KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial.

Suping Liu, Chi Fang, Xiaohua Wu, Jun Zhu, Guihao Ke

JAMA Netw Open 8(9) e2532501

PMID40971156
PMCIDPMC12449725
DOI10.1001/jamanetworkopen.2025.32501
发表日期2025-09-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

IMPORTANCE: Patients with cervical cancer exhibiting full-thickness (FT) and outer full-thickness (OFT) stromal invasion after radical hysterectomy face high risks of recurrence, yet optimal adjuvant radiotherapy strategies remain debated. OBJECTIVE: To determine if simultaneous integrated boost (SIB) radiotherapy increases 3-year progression-free survival (PFS) by 13% vs conventional chemoradiotherapy (CRT) among patients with cervical cancer exhibiting FT or OFT stromal invasion after surgery. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, single-center, randomized clinical superiority trial enrolled 466 patients in Shanghai Cancer Center with FIGO (International Federation of Gynecology and Obstetrics) 2018 stage IB to IIA and IIIC cervical cancer and pathologically confirmed FT or OFT stromal invasion from October 15, 2019, to September 20, 2024. Data were analyzed in October 2024. INTERVENTIONS: Patients were randomized to receive conventional CRT (50.4 Gy in 28 fractions plus cisplatin, 40 mg/m2/wk) or CRT plus SIB radiotherapy (58.8 Gy in 28 fractions). MAIN OUTCOMES AND MEASURES: The primary end point was 3-year PFS. Secondary end points included overall survival (OS), acute and late toxic effects, and progression patterns. All outcomes were analyzed under the intention-to-treat principle. RESULTS: A total of 466 patients with cervical cancer presenting with FT or OFT stromal invasion after radical hysterectomy were randomized (233 in non-SIB radiotherapy group: median age, 53 years [IQR, 46-59 years]; 233 in SIB radiotherapy group: median age, 55 years [IQR, 48-60 years]). At a median follow-up of 33 months (range, 8-54 months), SIB radiotherapy significantly improved 3-year PFS compared with conventional CRT (84.6% vs 76.8%; P = .04), corresponding to a 35.7% reduction in progression risk (hazard ratio [HR], 0.64; 95% CI, 0.42-0.99; P = .04). Multivariable analysis identified adenocarcinoma (HR, 2.68; 95% CI, 1.62-4.44; P < .001), adenosquamous carcinoma (HR, 2.66; 95% CI, 1.06-6.66; P = .04), tumor size of 4 cm or more (HR, 1.81; 95% CI, 1.17-2.81; P = .01), lymphovascular space invasion (HR, 2.88; 95% CI, 1.45-5.72; P = .003), and positive vaginal margins (HR, 4.60; 95% CI, 1.97-10.73; P < .001) as independent risk factors of poorer PFS, while SIB radiotherapy remained protective (HR, 0.59; 95% CI, 0.38-0.91; P = .02). Profiles of toxic effects were comparable between groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of postoperative patients with cervical cancer presenting with FT or OFT stromal invasion, SIB radiotherapy significantly enhanced PFS without increased toxic effects. The clinical benefits and comparable profiles of toxic effects support its integration into adjuvant care. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1900027272.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2.. Survival Outcomes With or Without Simultaneous Integrated Boost (SIB) Radiotherapy Kaplan-Meier curves for progression-free survival (PFS) (A), pelvic-specific PFS (B), and overall survival (C).

A

PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Pelvic-specific PFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
C

Overall survival

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Cross-Sectional Images of Simultaneous Integrated Boost Radiotherapy Contours
非 KM Figure
Figure 3Figure 3.. Risk Factors for Progression-Free Survival (PFS) and Overall Survival (OS) A, Univariable Cox proportional hazards regression analysis for PFS. B, Multivariable Cox proportional hazards regression analysis for PFS. C, Univariable Cox proportional hazards regression analysis for OS. D, Multivariable Cox proportional hazards regression analysis for OS. FIGO indicates International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; and SIB, simultaneous integrated boost.
非 KM Figure